30 closest matches · ranked by relevance
Primary Inoperable Thymoma · Local Recurrent Thymoma
Primary: Percent Change in Tumor Volume From Baseline to EOS — -37.38 percentage of tumor volume
Thymoma · Thymic Carcinoma · Thymic Carcinoid
Primary: Objective Response Rate (Partial Response (PR)+Complete Response (CR)) to IMC-A12 Monotherapy in Patients With Advanced or Recurrent Thymoma or Thymic Carcinoma. — 0; 0…
Thymoma
Primary: Percent of Patients With Objective Response — 7.1 percentage of participants
Thymoma · Thymus Neoplasms
Primary: Percentage of Participants With an Objective Response (Partial Response (PR) + Complete Response (CR) for Sunitinib in Participants With Relapsed or Refractory Thymoma…
Thymoma · Thymic Carcinoma
Primary: Objective Response Rate (Complete and Partial Response) — 26.7; 9.1 percentage of participants
Thymoma · Thymic Carcinoma
Primary: Number of Participants With a Partial Response — 2; 0 Participants
Thymoma · Thymus Cancer · Thymic Carcinoma
Primary: Overall Response Rate (ORR) — 0; 6; 6 Participants
Thymoma · Thymic Carcinoma
Primary: Best Overall Response by RECIST Criteria (Version 1.0) — 3; 0; 5; 6 Participants
Myasthenia Gravis
Primary: Time-weighted Average Quantitative Myasthenia Gravis Weakness Score Over 3 Years — 6.15; 8.99 units on a scale
Carcinoma, Non-Small-Cell Lung
Primary: Disease Control Rate (DCR) After 12 Weeks Induction — 0.742 proportion of participants
Locally Advanced Thymic Carcinoma · Metastatic Thymic Carcinoma · Recurrent Thymic Carcinoma
Primary: Progression-free Survival — 8; 7 Months
Poor Thymic Function · Immunodeficiency · Athymia
Primary: Survival Rate at End of 1 Year — 90.9 percentage of participants
Synchronous Metastasized Breast Cancer · Circulating Tumor Cells
Primary: Overall Survival (OS) — 34.6; 56.2 months — p=0.042
Carcinoma, Non-Small-Cell Lung
Primary: Time to Death or Distant Metastasis — 30.7 months
Malignant Non-small Cell Neoplasm of Lung Stage Ia
Primary: Local Tumor Control Rate 1 Year After Percutaneous Radiofrequency Ablation (RFA) — 5 Participants
Non-small Cell Lung Cancer
Primary: Progression Free Survival (PFS) at 18-month — 65.5; 66.3 Percentage of participants
Complete DiGeorge Anomaly · DiGeorge Syndrome · DiGeorge Anomaly
Primary: Survival Rate at End of 1 Year — 79.3 percentage of participants
Neuroendocrine Tumors · Neuroendocrine Neoplasm of Lung
Primary: Clinical Benefit Rate (CBR) — 0; 0; 0; 1 Participants
Non-small Cell Lung Cancer
Primary: Overall Survival (OS) Time — 32.4; 32.2 Months — p=0.828
Mesothelioma
Primary: Change in Ratio of Intratumoral Cytotoxic T Cells to Regulatory T Cells (CD8/Treg) — 8.6 no unit of ratios with same units(%) — p=0.109
DiGeorge Anomaly · Complete DiGeorge Anomaly · Complete Atypical DiGeorge Anomaly
Primary: Survival at 1 Year Post-CTTI — 71 % of participants who survive to 1 year
Anaplastic Thyroid Cancer
Primary: Overall Response (OR) — 0; 3; 3; 1 Participants
DiGeorge Syndrome · Complete Typical DiGeorge Anomaly
Primary: Survival at 1 Year Post-Cultured Thymus Tissue Implantation (CTTI) — 72 % of participants who survive to 1 year
Carcinoma, Non-Small-Cell Lung · Carcinoma, Small Cell Lung · Carcinoma, Thymic
Primary: Percentage of Enrolled Participants Testing Positive for Genomic Abnormality — 28.5; 44.2; 0; 24.9 percentage of participants
Lymphoma · Leukemia
Primary: Composite Success Rate — 100; 75; 84 Percentage of participants
Liposarcoma
Primary: Cumulative Incidence Rate of Local Recurrence and Competing Risks (All Patients) — 16.89; 10.42 percentage of participants
Esophageal Cancer
Primary: Pathologic Complete Response (PCR) Rate
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
Lung Cancer
Primary: Pathologic Complete Response Rate — 0 Percentage of participants
Non-small Cell Lung Cancer Stage IV
Primary: Efficacy of Atezolizumab + CBDCA + Pemetrexed by Evaluating PFS Rate — 62.2 percentage of participants